Entries by speedbird

Auspherix Shortlisted for Biotech and Money’s ‘Start-Up UK Company of the Year’ Award

Auspherix, an early stage anti-infectives company, today announces that it has been shortlisted for the ‘Start-Up UK Company of the Year’ category of the inaugural Biotech and Money 2016 Awards. Auspherix was nominated for the award and selected as a shortlisted finalist for its focus on developing new antibiotics in the fight against antimicrobial resistance and […]

Auspherix Appoints Experienced Anti-Infectives Clinician to Scientific Advisory Board

4 July 2016 Auspherix, an early stage anti-infectives company, today announces that it has expanded its Scientific Advisory Board (SAB) with the appointment of highly experienced clinician, Professor William Hope. William’s career to date has focused on research in antimicrobial pharmacokinetics and pharmacodynamics, mathematic modelling of antimicrobial agents and individualisation of antimicrobial therapy.  He is an […]

Auspherix Welcomes O’Neill Report on Drug Resistant Infections

19 May 2016 Auspherix, an early stage anti-infectives company, today welcomes the O’Neill report on antimicrobial resistance “Tackling Drug-Resistant Infections Globally” which calls for large pharmaceutical companies to participate in the development of new treatments. Research has almost halted in the past 25 years because antibiotics are expensive to develop and provide relatively small returns. Dr […]

Management Update

Co-founder of Auspherix Ltd. and VP Biology, Dr Dagmar Alber, has left the business to pursue new opportunities. Dagmar’s expertise and passion has been pivotal to Auspherix’s success. We thank Dagmar for her contribution and wish her every success for the future.

Auspherix, as part of the BEAM Alliance, Signs Industry Declaration on Beating Antibiotic Resistance

Auspherix, an early stage anti-infectives company, today announces that it has signed the BEAM Alliance’s call to governements and industry to work in parallel to take comprehensive action against drug-resistant infections, launched today at the World Economic Forum in Davos, Switzerland.  Full release below. GLOBAL PHARMACEUTICAL INDUSTRY CALLS ON GOVERNMENTS TO WORK WITH THEM TO BEAT […]

Auspherix Appoints Dr. Neil Miller as Chief Scientific Officer

Stevenage, UK, 2 December 2015 – Auspherix Limited (UK), an early stage anti-infectives company, has announced the appointment of Dr. Neil Miller as its Chief Scientific Officer, effective 1 December. As CSO, Dr Miller will take full responsibility for driving forward the Company’s antibiotic R&D programmes, both in house and through partners, into clinical Proof-of-Concept […]